Relay Therapeutics, Inc.
Company Stats
- Market Cap
- $4.0B
- as of Sep 30, 2026
- Shares Outstanding
- 219.1M
- Free Float
- 54.5%
Income Statement
- Revenue
- $15.4M
- Operating Income
- -$302.7M
- Net Income
- -$276.5M
- EBITDA
- -$299.2M
- Revenue Growth, 3Y
- 123.2%
- FCF Margin, 3Y Avg
- -1745.8%
- FCF Margin, Worst Year
- -2509.5%
Cash Flow
- Free Cash Flow
- -$235.9M
- FCF Yield
- -6.0%
- Owner FCF Yield
- -7.5%
Balance Sheet
- Cash & Equivalents
- $84.0M
Returns & Capital
- SBC, 3Y Avg
- $80.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $15.4M | -$235.9M | -1536.1% |
| FY2024 | $10.0M | -$251.1M | -2509.5% |
| FY2023 | $25.5M | -$304.4M | -1191.7% |
| FY2022 | $1.4M | -$238.6M | -17273.9% |
| FY2021 | $3.0M | -$77.9M | -2571.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back